Xue-Yan Cui
- Senior Researcher; MD, PhD
- +47 23 07 21 84
Publications 2023
Safety of butylphthalide and edaravone in patients with ischemic stroke: a multicenter real-world study
J Geriatr Cardiol, 20 (4), 293-308
DOI 10.26599/1671-5411.2023.04.002, PubMed 37122986
Publications 2022
FSAP Protects against Histone-Mediated Increase in Endothelial Permeability In Vitro
Int J Mol Sci, 23 (22)
DOI 10.3390/ijms232213706, PubMed 36430180
SARS-CoV-2 vaccines are not associated with hypercoagulability in apparently healthy people
Res Pract Thromb Haemost, 7 (1), 100002
DOI 10.1016/j.rpth.2022.100002, PubMed 36448024
Publications 2021
Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia
Sci Rep, 11 (1), 5127
DOI 10.1038/s41598-021-84695-8, PubMed 33664415
Publications 2017
A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7
Thromb Res, 157, 111-116
DOI 10.1016/j.thromres.2017.07.013, PubMed 28734156
Publications 2016
EPAS1/HIF-2 alpha-mediated downregulation of tissue factor pathway inhibitor leads to a pro-thrombotic potential in endothelial cells
Biochim Biophys Acta, 1862 (4), 670-678
DOI 10.1016/j.bbadis.2016.01.017, PubMed 26826018
Publications 2013
Hypoxia influences stem cell-like properties in multidrug resistant K562 leukemic cells
Blood Cells Mol Dis, 51 (3), 177-84
DOI 10.1016/j.bcmd.2013.05.003, PubMed 23725749